Daratumumab/hyaluronidase is indicated for the treatment of adults with multiple myeloma:
• in combination with bortezomib, melphalan and prednisone (D-VMP) in newly diagnosed adults who are ineligible for autologous stem cell transplant
• in combination with lenalidomide and dexamethasone (D-Rd) in newly diagnosed adults who are ineligible for autologous stem cell transplant and in people with relapsed or refractory multiple myeloma who have received at least one prior therapy
• in combination with bortezomib and dexamethasone (D-Vd) in adults who have received at least one prior therapy as monotherapy, in adults who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
• It was approved for use in the United States in May 2020.